185 related articles for article (PubMed ID: 38389324)
1. Distinct phenotype of SARS-CoV-2 Omicron BA.1 in human primary cells but no increased host range in cell lines of putative mammalian reservoir species.
Essaidi-Laziosi M; Pérez-Rodríguez FJ; Alvarez C; Sattonnet-Roche P; Torriani G; Bekliz M; Adea K; Lenk M; Suliman T; Preiser W; Müller MA; Drosten C; Kaiser L; Eckerle I
Virus Res; 2024 Jan; 339():199255. PubMed ID: 38389324
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating.
Tanneti NS; Patel AK; Tan LH; Marques AD; Perera RAPM; Sherrill-Mix S; Kelly BJ; Renner DM; Collman RG; Rodino K; Lee C; Bushman FD; Cohen NA; Weiss SR
mBio; 2024 Apr; 15(4):e0312923. PubMed ID: 38477472
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.
Nchioua R; Schundner A; Kmiec D; Prelli Bozzo C; Zech F; Koepke L; Graf A; Krebs S; Blum H; Frick M; Sparrer KMJ; Kirchhoff F
J Virol; 2022 Jun; 96(11):e0059422. PubMed ID: 35543509
[TBL] [Abstract][Full Text] [Related]
4. The Omicron Variant BA.1.1 Presents a Lower Pathogenicity than B.1 D614G and Delta Variants in a Feline Model of SARS-CoV-2 Infection.
Martins M; do Nascimento GM; Nooruzzaman M; Yuan F; Chen C; Caserta LC; Miller AD; Whittaker GR; Fang Y; Diel DG
J Virol; 2022 Sep; 96(17):e0096122. PubMed ID: 36000850
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 nonstructural protein 6 from Alpha to Omicron: evolution of a transmembrane protein.
Feng S; O'Brien A; Chen DY; Saeed M; Baker SC
mBio; 2023 Aug; 14(4):e0068823. PubMed ID: 37477426
[TBL] [Abstract][Full Text] [Related]
6. Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.
Osterman A; Krenn F; Iglhaut M; Badell I; Lehner A; Späth PM; Stern M; Both H; Bender S; Muenchhoff M; Graf A; Krebs S; Blum H; Grimmer T; Durner J; Czibere L; Dächert C; Grzimek-Koschewa N; Protzer U; Kaderali L; Baldauf HM; Keppler OT
Med Microbiol Immunol; 2023 Oct; 212(5):307-322. PubMed ID: 37561226
[TBL] [Abstract][Full Text] [Related]
7. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
Akkız H
Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
[TBL] [Abstract][Full Text] [Related]
8. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs.
Bekliz M; Adea K; Vetter P; Eberhardt CS; Hosszu-Fellous K; Vu DL; Puhach O; Essaidi-Laziosi M; Waldvogel-Abramowski S; Stephan C; L'Huillier AG; Siegrist CA; Didierlaurent AM; Kaiser L; Meyer B; Eckerle I
Nat Commun; 2022 Jul; 13(1):3840. PubMed ID: 35787633
[TBL] [Abstract][Full Text] [Related]
9. Modelling the viral dynamics of the SARS-CoV-2 Delta and Omicron variants in different cell types.
McCormack CP; Yan AWC; Brown JC; Sukhova K; Peacock TP; Barclay WS; Dorigatti I
J R Soc Interface; 2023 Aug; 20(205):20230187. PubMed ID: 37553993
[TBL] [Abstract][Full Text] [Related]
10. Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.
Prince T; Dong X; Penrice-Randal R; Randle N; Hartley C; Goldswain H; Jones B; Semple MG; Baillie JK; Openshaw PJM; Turtle L; Hughes GL; Anderson ER; Patterson EI; Druce J; Screaton G; Carroll MW; Stewart JP; Hiscox JA
mSphere; 2022 Jun; 7(3):e0091321. PubMed ID: 35491827
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 variants Alpha, Beta, Delta and Omicron show a slower host cell interferon response compared to an early pandemic variant.
Laine L; Skön M; Väisänen E; Julkunen I; Österlund P
Front Immunol; 2022; 13():1016108. PubMed ID: 36248817
[TBL] [Abstract][Full Text] [Related]
12. Experimental co-infection of calves with SARS-CoV-2 Delta and Omicron variants of concern.
Cool K; Gaudreault NN; Trujillo JD; Morozov I; McDowell CD; Bold D; Kwon T; Balaraman V; Assato P; Madden DW; Mantlo E; Souza-Neto J; Matias-Ferreyra F; Retallick J; Singh G; Schotsaert M; Carossino M; Balasuriya UBR; Wilson WC; Pogranichniy RM; García-Sastre A; Richt JA
Emerg Microbes Infect; 2024 Dec; 13(1):2281356. PubMed ID: 37938158
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells.
Metzler M; Tharyan RG; Klann K; Grikscheit K; Bojkova D; Cinatl J; Tascher G; Ciesek S; Münch C
Mol Cell Proteomics; 2023 May; 22(5):100537. PubMed ID: 37001587
[TBL] [Abstract][Full Text] [Related]
14. Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1.
Nchioua R; Schundner A; Klute S; Koepke L; Hirschenberger M; Noettger S; Fois G; Zech F; Graf A; Krebs S; Braubach P; Blum H; Stenger S; Kmiec D; Frick M; Kirchhoff F; Sparrer KM
Life Sci Alliance; 2023 Jun; 6(6):. PubMed ID: 36977594
[TBL] [Abstract][Full Text] [Related]
15. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating.
Tanneti NS; Patel AK; Tan LH; Marques AD; Perera RAPM; Sherrill-Mix S; Kelly BJ; Renner DM; Collman RG; Rodino K; Lee C; Bushman FD; Cohen NA; Weiss SR
bioRxiv; 2023 Dec; ():. PubMed ID: 37662273
[TBL] [Abstract][Full Text] [Related]
16. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
Pérez-Vargas J; Shapira T; Olmstead AD; Villanueva I; Thompson CAH; Ennis S; Gao G; De Guzman J; Williams DE; Wang M; Chin A; Bautista-Sánchez D; Agafitei O; Levett P; Xie X; Nuzzo G; Freire VF; Quintana-Bulla JI; Bernardi DI; Gubiani JR; Suthiphasilp V; Raksat A; Meesakul P; Polbuppha I; Cheenpracha S; Jaidee W; Kanokmedhakul K; Yenjai C; Chaiyosang B; Teles HL; Manzo E; Fontana A; Leduc R; Boudreault PL; Berlinck RGS; Laphookhieo S; Kanokmedhakul S; Tietjen I; Cherkasov A; Krajden M; Nabi IR; Niikura M; Shi PY; Andersen RJ; Jean F
Antiviral Res; 2023 Jan; 209():105484. PubMed ID: 36503013
[TBL] [Abstract][Full Text] [Related]
17. Ancestral Lineage of SARS-CoV-2 Is More Stable in Human Biological Fluids than Alpha, Beta, and Omicron Variants of Concern.
Kwon T; Gaudreault NN; Meekins DA; McDowell CD; Cool K; Richt JA
Microbiol Spectr; 2023 Feb; 11(1):e0330122. PubMed ID: 36688691
[TBL] [Abstract][Full Text] [Related]
18. The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection.
Martins M; Nooruzzaman M; Cunningham JL; Ye C; Caserta LC; Jackson N; Martinez-Sobrido L; Fang Y; Diel DG
J Virol; 2024 Mar; 98(3):e0190223. PubMed ID: 38421180
[TBL] [Abstract][Full Text] [Related]
19. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability.
Hirose R; Itoh Y; Ikegaya H; Miyazaki H; Watanabe N; Yoshida T; Bandou R; Daidoji T; Nakaya T
Clin Microbiol Infect; 2022 Nov; 28(11):1486-1491. PubMed ID: 35640841
[TBL] [Abstract][Full Text] [Related]
20. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
